Mereo BioPharma Group plc

NASDAQ:MREO

Biotechnology

Healthcare
$0.32 +9.69%

+$0.03 today

Market cap
$51.08M
Beta
0.28
P/E (TTM)
-1.4
EPS (TTM)
-$0.22
52W Low $0.20High $3.05

Volume 1.26M

Average 3.36M

MREO Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Mereo BioPharma Group plcNASDAQ: MREO

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue remains negative

Q1 FY2026 revenue was $0, compared with $0 a year earlier. Trailing-twelve-month revenue was $500K.

Context

  • Revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 4 analysts of $1.78M (+255.0%) for the fiscal year ending Dec 2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$500K— YoY
LTMMar 2026
$500K— YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter—+600.0%—
1 year—+255.0%—
3-year CAGR—+163.5%—
5-year CAGR+179.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
500K USD
Year-over-year change
—
4-year CAGR
-68.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How MREO compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
MREO Competitors
Revenue for MREO and competitors
Company Period LTM YoY 3-year CAGR
PRQRProQR Therapeutics N.V.LTM Mar 2026€13.44M EUR-29.2%+62.0%
IMMPImmutep LimitedFY2025A$5.04M AUD+31.3%+209.4%
ACIUAC Immune S.A.LTM Mar 2026CHF 3.7M CHF-86.9%-3.2%
SLNSilence Therapeutics plcLTM Mar 2026$921.49K USD—-68.4%
MREOMereo BioPharma Group plcLTM Mar 2026$500K USD——
CADLCandel Therapeutics, Inc.LTM Mar 2026$0 USD——
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$0 USD-100.0%—
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$0 USD——
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$0 USD——
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$0 USD——
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$0 USD——
Peer median (excluding MREO) —-58.0%+29.4%

Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue49.21M010M0500K
Cost of Revenue24.17M(257.44K)2.57M1.09M133K
Gross Profit25.04M257.44K7.43M(1.09M)367K
Gross Margin50.9%—74.3%—73.4%
Research & Development31.8M30.75M17.42M20.93M17.77M
Selling, General & Admin21.5M23.18M18.42M26.43M23.01M
Operating Expenses53.3M53.92M35.84M47.36M38.62M
Depreciation & Amortization866.47K895.5K1.06M1.09M1.15M
EBITDA25.49M(39.98M)(26.06M)(40.8M)(40.47M)
EBITDA Margin51.8%—-260.6%—-8094.8%
Operating Income(28.26M)(53.67M)(28.42M)(47.36M)(38.26M)
Operating Margin-57.4%—-284.2%—-7651.4%
Interest Income1.38K696K2.13M3.04M2.17M
Interest Expense5.22M3.36M2.88M1.37M255K
Other Income / Expenses47.48M9.21M(1.58M)4.11M(3.62M)
Income Before Tax19.22M(44.46M)(30M)(43.25M)(41.88M)
Pre-Tax Margin39.1%—-300.0%—-8375.6%
Income Tax Expense2.05M(2.34M)(532K)00
Net Income17.17M(42.12M)(29.47M)(43.25M)(41.88M)
Net Margin34.9%—-294.7%—-8375.6%
EPS (Basic)749.65(1,750.35)(1,100.22)(0.29)(0.26)
EPS (Diluted)749.65(1,750.35)(1,100.22)(0.29)(0.26)
Weighted Avg Shares116.73M120.64M131.89M147.92M159.42M
Weighted Avg Shares (Diluted)116.73M120.64M131.89M147.92M159.42M

Mereo BioPharma Group plc

NASDAQ:MREO

Intrinsic Alpha fair value

Locked

Current Price

$0.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.